Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ProtAffin, a biotechnology company, has commenced dosing healthy volunteers in a Phase 1 study of PA401, in the UK.
Subscribe to our email newsletter
PA401, the novel investigational anti-inflammatory product, is a modified form of the human chemokine IL-8.
By acting as a potent, targeted anti-inflammatory protein, PA401 prevents the infiltration of neutrophils which is a feature of many respiratory diseases such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF).
ProtAffin chief development officer Mike Bartley said, "Our extensive preclinical studies into the anti-inflammatory properties of PA401 suggest that it is a promising candidate for the steroid-resistant inflammation which causes significant morbidity and mortality in diseases such as COPD and cystic fibrosis. We expect to complete the study by the end of 2012."
ProtAffin chief executive officer Jason Slings said PA401 was discovered using ProtAffin’s proprietary CellJammer discovery platform.
"We are confident that we will establish targeting glycans with biopharmaceuticals as a new therapeutic modality within the biopharmaceuticals industry," Slings added.